{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:35:33Z","timestamp":1780479333421,"version":"3.54.1"},"reference-count":126,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.trre.2018.11.001","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T22:27:00Z","timestamp":1542148020000},"page":"55-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Immunosuppressive drugs and the gastrointestinal tract in renal transplant patients"],"prefix":"10.1016","volume":"33","author":[{"given":"Merel M.","family":"Tielemans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerben A.J.","family":"van Boekel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric T.","family":"Tjwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4935-9765","authenticated-orcid":false,"given":"Luuk B.","family":"Hilbrands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2018.11.001_bb0005","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/01.tp.0000251923.14697.f5","article-title":"Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients","volume":"83","author":"Ekberg","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0010","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.ajkd.2007.11.013","article-title":"Incidence and risk factors for diarrhea following kidney transplantation and association with graft loss and mortality","volume":"51","author":"Bunnapradist","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2018.11.001_bb0015","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/j.1432-2277.2005.00176.x","article-title":"Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review","volume":"18","author":"Denhaerynck","year":"2005","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2018.11.001_bb0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijpharm.2013.05.033","article-title":"From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation","volume":"452","author":"Knops","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.trre.2018.11.001_bb0025","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1111\/ajt.12955","article-title":"Novel Once-Daily#spcent;Extended-Release Tacrolimus (LCPT) Versus Twice-Daily Tacrolimus in De Novo Kidney Transplants: One-Year results of phase III,#spcent;Double-blind, Randomized Trial","volume":"14","author":"Budde","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2018.11.001_bb0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clpt.2003.10.008","article-title":"Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens","volume":"75","author":"von Richter","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.trre.2018.11.001_bb0040","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0022-3565(24)37149-6","article-title":"Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism","volume":"283","author":"Paine","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.trre.2018.11.001_bb0045","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/j.1440-1681.2007.04691.x","article-title":"Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum","volume":"34","author":"Canaparo","year":"2007","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.trre.2018.11.001_bb0050","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00003088-199834060-00002","article-title":"Clinical pharmacokinetics of mycophenolate mofetil","volume":"34","author":"Bullingham","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2018.11.001_bb0055","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1046\/j.1600-6143.2005.00779.x","article-title":"Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2","volume":"5","author":"Hesselink","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00007691-200104000-00005","article-title":"Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid","volume":"23","author":"van Gelder","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.trre.2018.11.001_bb0065","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/ki.2013.517","article-title":"Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients","volume":"85","author":"Colom","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2018.11.001_bb0070","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1681\/ASN.2005101070","article-title":"Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients","volume":"17","author":"van Hest","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2018.11.001_bb0075","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/003655298750027290","article-title":"Azathioprine: state of the art in inflammatory bowel disease","volume":"225","author":"Sandborn","year":"1998","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.trre.2018.11.001_bb0080","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1023\/A:1005573229786","article-title":"Sequential group trial to determine gastrointestinal site of absorption and systemic exposure of azathioprine","volume":"45","author":"Gervasio","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.trre.2018.11.001_bb0085","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1111\/j.1600-6143.2012.04232.x","article-title":"Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs","volume":"12","author":"Jacobson","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0090","article-title":"Longitudinal pharmacokinetics of mycophenolic acid in elderly renal transplant recipients compared to a younger control group: Data from the nEverOld Trial","author":"Romano","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.trre.2018.11.001_bb0095","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.transproceed.2005.02.076","article-title":"Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy","volume":"37","author":"Nakamura","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2018.11.001_bb0100","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1016\/j.transproceed.2005.11.029","article-title":"Optimal initial dose of orally administered cyclosporine following intravenous cyclosporine therapy","volume":"37","author":"Ishizawa","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2018.11.001_bb0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1034\/j.1399-0012.2000.140301.x","article-title":"Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics","volume":"14","author":"Pescovitz","year":"2000","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0110","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/bcp.12420","article-title":"Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers","volume":"78","author":"Stifft","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.trre.2018.11.001_bb0115","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/j.1552-4604.1991.tb01890.x","article-title":"The pharmacokinetics and colonic tissue concentrations of cyclosporine after i.v., oral, and enema administration","volume":"31","author":"Sandborn","year":"1991","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.trre.2018.11.001_bb0120","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0140-6736(90)90289-H","article-title":"Self-management of adrenal insufficiency by rectal hydrocortisone","volume":"335","author":"Newrick","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2018.11.001_bb0125","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1034\/j.1399-3046.2002.01052.x","article-title":"Efficacy and pharmacokinetics of tacrolimus oral suspension in pediatric liver transplant recipients","volume":"6","author":"Reding","year":"2002","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0130","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/apt.14022","article-title":"Sublingual tacrolimus administration provides similar drug exposure to per-oral route employing lower doses in liver transplantation: a pilot study","volume":"45","author":"Solari","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.trre.2018.11.001_bb0135","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00007890-199610150-00026","article-title":"Induction of immunosuppression by microemulsion cyclosporine in liver transplantation","volume":"62","author":"Rasmussen","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0140","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1099-081X(199907)20:5<249::AID-BDD181>3.0.CO;2-9","article-title":"Conversion from liquid to solid rapamycin formulations in stable renal allograft transplant recipients","volume":"20","author":"Kelly","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.trre.2018.11.001_bb0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-200746010-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients","volume":"46","author":"Staatz","year":"2007","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2018.11.001_bb0150","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/MOG.0b013e328358d619","volume":"28","author":"Gastroparesis","year":"2012","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.trre.2018.11.001_bb0155","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/0140-6736(91)92302-I","article-title":"First-pass metabolism of cyclosporin by the gut","volume":"338","author":"Kolars","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2018.11.001_bb0160","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1124\/dmd.104.001503","article-title":"The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients","volume":"32","author":"Kuypers","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.trre.2018.11.001_bb0165","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1097\/00007890-199911270-00009","article-title":"Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine","volume":"68","author":"Maes","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0170","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2125.2006.02813.x","article-title":"Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients","volume":"63","author":"Naesens","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.trre.2018.11.001_bb0175","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1034\/j.1399-0012.2003.00016.x","article-title":"Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients","volume":"17","author":"Maes","year":"2003","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0180","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1034\/j.1399-3046.2001.00056.x","article-title":"Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation","volume":"5","author":"Hasegawa","year":"2001","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0185","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/lt.500040502","article-title":"Pharmacokinetics of tacrolimus and cyclosporine in short-bowel syndrome","volume":"4","author":"Thielke","year":"1998","journal-title":"Liver Transpl Surg"},{"key":"10.1016\/j.trre.2018.11.001_bb0190","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/00007691-200312000-00004","article-title":"Dose-adjusted cyclosporine c2 in a patient with jejunoileal bypass as compared to seven other liver transplant recipients","volume":"25","author":"Chenhsu","year":"2003","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.trre.2018.11.001_bb0195","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ndt\/17.2.318","article-title":"Disappearance of measurable mycophenolate mofetil (Cell Cept) in a patient with a renal transplant and an ileostomy","volume":"17","author":"Goransson","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0200","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/00365528309181635","article-title":"Bioavailability of prednisolone in patients with intestinal malabsorption: the importance of measuring serum protein-binding","volume":"18","author":"Bergrem","year":"1983","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.trre.2018.11.001_bb0205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1399-0012.2007.00783.x","article-title":"Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study","volume":"22","author":"Rogers","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0210","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1517\/17425255.2012.722757","article-title":"The effects of gastric bypass surgery on drug absorption and pharmacokinetics","volume":"8","author":"Brocks","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.trre.2018.11.001_bb0215","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.12975","article-title":"Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve gastrectomy","volume":"31","author":"Diwan","year":"2017","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0220","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.transproceed.2013.11.040","article-title":"Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients","volume":"46","author":"Nakamura","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2018.11.001_bb0225","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2125.2005.02389.x","article-title":"Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract","volume":"60","author":"Thorn","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.trre.2018.11.001_bb0230","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1034\/j.1600-6143.2002.21018.x","article-title":"Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients","volume":"2","author":"Maes","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0235","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus#spcent;ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data","volume":"331","author":"Webster","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2018.11.001_bb0240","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/ndt\/gfq401","article-title":"High frequency of ulcers, not associated with Helicobacter pylori, in the stomach in the first year after kidney transplantation","volume":"26","author":"Telkes","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0245","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1034\/j.1399-0012.2002.01012.x","article-title":"Upper gastrointestinal complications after renal transplantation: a 3-yr sequential study","volume":"16","author":"Logan","year":"2002","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0250","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/01.TP.0000070434.73865.7A","article-title":"A case of tacrolimus (FK506)-induced pancreatitis and fatality 2 years postcadaveric renal transplant","volume":"76","author":"Ogunseinde","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0255","doi-asserted-by":"crossref","first-page":"72","DOI":"10.6002\/ect.2012.0106","article-title":"Diabetic ketoacidosis associated with acute pancreatitis in a heart transplant recipient treated with tacrolimus","volume":"11","author":"Im","year":"2013","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0260","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00228-012-1355-x","article-title":"ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients","volume":"69","author":"Garcia","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.trre.2018.11.001_bb0265","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1600-0765.2007.00986.x","volume":"42","author":"Sukkar","year":"2007","journal-title":"J Periodontal Res"},{"key":"10.1016\/j.trre.2018.11.001_bb0270","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1097\/00007890-199806270-00012","article-title":"Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients","volume":"65","author":"Nash","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0275","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0272-6386(88)80065-9","article-title":"Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients","volume":"12","author":"Yoshimura","year":"1988","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2018.11.001_bb0280","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1432-2277.2010.01167.x","article-title":"Systemic influence of immunosuppressive drugs on small and large bowel transport and barrier function","volume":"24","author":"Malinowski","year":"2011","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2018.11.001_bb0285","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/01.TP.0000151630.25127.3A","article-title":"Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy","volume":"79","author":"Mahe","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0290","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0295","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/01.TP.0000056639.74982.F9","article-title":"Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil","volume":"75","author":"van Gelder","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0300","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2018.11.001_bb0305","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ajhp\/57.5.437","article-title":"Sirolimus: a new agent for prevention of renal allograft rejection","volume":"57","author":"Vasquez","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.trre.2018.11.001_bb0310","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/j.gastro.2015.03.046","article-title":"Rapamycin Inhibition of mTOR Reduces Levels of the Na+\/H+ Exchanger 3 in Intestines of mice and Humans, Leading to Diarrhea","volume":"149","author":"Yang","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trre.2018.11.001_bb0315","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1023\/A:1026610404647","article-title":"Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits","volume":"43","author":"Dias","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.trre.2018.11.001_bb0320","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.transproceed.2006.02.123","article-title":"Sirolimus-induced intractable chronic diarrhea: a case report","volume":"38","author":"Alkhatib","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2018.11.001_bb0325","first-page":"1321","article-title":"European Mycophenolate Mofetil Cooperative Study Group","volume":"345","author":"Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2018.11.001_bb0330","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00007890-199604150-00008","article-title":"Randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group","volume":"61","author":"Blinded","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0335","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","article-title":"Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group","volume":"60","author":"Sollinger","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0340","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00007890-200107150-00014","article-title":"Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients","volume":"72","author":"Squifflet","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0345","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/j.1600-6143.2005.00778.x","article-title":"Mycophenolate sodium does not reduce the incidence of GI adverse events compared with mycophenolate mofetil","volume":"5","author":"Meier-Kriesche","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0350","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/j.1600-6143.2007.01859.x","article-title":"Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients","volume":"7","author":"Heller","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0355","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1432-2277.2004.tb00471.x","article-title":"Villous atrophy induced by mycophenolate mofetil in renal-transplant patients","volume":"17","author":"Kamar","year":"2004","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2018.11.001_bb0360","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/01.TP.0000053753.43268.F0","article-title":"Erosive enterocolitis in mycophenolate mofetil-treated#spcent;renal-transplant recipients with persistent afebrile diarrhea","volume":"75","author":"Maes","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0365","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1365-2125.2010.03625.x","article-title":"Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele","volume":"69","author":"Woillard","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.trre.2018.11.001_bb0370","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1067\/mcp.2001.113183","article-title":"The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups","volume":"69","author":"Mancinelli","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.trre.2018.11.001_bb0375","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0041-1345(98)01531-0","article-title":"Mycophenolate mofetil-induced colonic ulceration in renal transplant recipients","volume":"31","author":"Golconda","year":"1999","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2018.11.001_bb0380","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.transproceed.2006.12.028","article-title":"Oral ulcers produced by mycophenolate mofetil in two liver transplant patients","volume":"39","author":"Naranjo","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2018.11.001_bb0385","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/gut.2007.139972","article-title":"Crohn's-like enterocolitis associated with mycophenolic acid treatment","volume":"57","author":"Dost","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.trre.2018.11.001_bb0390","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/TP.0b013e31822527ca","article-title":"Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium","volume":"92","author":"Ortega","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0395","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1016\/j.transproceed.2009.08.078","article-title":"Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients","volume":"41","author":"Burg","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2018.11.001_bb0400","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1046\/j.1600-6143.2003.00321.x","article-title":"Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study","volume":"4","author":"Budde","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0405","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/ndt\/gfi009","article-title":"Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium","volume":"20","author":"Kamar","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0410","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/ard.41.Suppl_1.44","article-title":"Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities","volume":"41","author":"Whisnant","year":"1982","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.trre.2018.11.001_bb0415","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/S0016-5085(03)00405-0","article-title":"Severe villus atrophy and chronic malabsorption induced by azathioprine","volume":"124","author":"Ziegler","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trre.2018.11.001_bb0420","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1600-6143.2010.03423.x","article-title":"Duodenal villous atrophy: a cause of chronic diarrhea after solid-organ transplantation","volume":"11","author":"Weclawiak","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0425","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1586\/17474124.2015.992879","article-title":"Thiopurine-induced pancreatitis in inflammatory bowel diseases","volume":"9","author":"Ledder","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.trre.2018.11.001_bb0430","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000051882","article-title":"Severe life-threatening diarrhea caused by azathioprine but not by 6-mercaptopurine","volume":"63","author":"Marbet","year":"2001","journal-title":"Digestion"},{"key":"10.1016\/j.trre.2018.11.001_bb0435","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004587","article-title":"Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis","volume":"4","author":"Narum","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.trre.2018.11.001_bb0440","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11894-012-0245-9","article-title":"Drug-induced pancreatitis","volume":"14","author":"Nitsche","year":"2012","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.trre.2018.11.001_bb0445","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00006676-199508000-00009","article-title":"Effect of chronic administration of hydrocortisone on the induction and evolution of acute pancreatitis induced by cerulein","volume":"11","author":"Pescador","year":"1995","journal-title":"Pancreas"},{"key":"10.1016\/j.trre.2018.11.001_bb0450","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1067\/mge.2002.122614","article-title":"Octreotide versus hydrocortisone versus placebo in the prevention of post-ERCP pancreatitis: a multicenter randomized controlled trial","volume":"55","author":"Manolakopoulos","year":"2002","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.trre.2018.11.001_bb0455","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4132\/KoreanJPathol.2013.47.2.163","article-title":"Silent Colonic Malakoplakia in a Living-Donor Kidney Transplant Recipient Diagnosed during Annual Medical Examination","volume":"47","author":"Bae","year":"2013","journal-title":"Korean J Pathol"},{"key":"10.1016\/j.trre.2018.11.001_bb0460","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0465","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0470","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3109\/00365521.2014.946087","article-title":"Two cases of ulcerative colitis developing in rheumatoid arthritis patients during abatacept therapy","volume":"49","author":"Motohashi","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.trre.2018.11.001_bb0475","doi-asserted-by":"crossref","first-page":"8660","DOI":"10.3748\/wjg.v23.i48.8660","article-title":"Stricturing Crohn's disease-like colitis in a patient treated with belatacept","volume":"23","author":"Bozon","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.trre.2018.11.001_bb0480","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1592\/phco.24.5.532.33357","article-title":"Tacrolimus toxicity associated with concomitant metoclopramide therapy","volume":"24","author":"Prescott","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.trre.2018.11.001_bb0485","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2125.1996.03636.x","article-title":"Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients","volume":"41","author":"Bullingham","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.trre.2018.11.001_bb0490","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/rheumatology\/keq238","article-title":"Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil","volume":"49","author":"Schaier","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.trre.2018.11.001_bb0495","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1600-6143.2009.02682.x","article-title":"Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study","volume":"9","author":"Kofler","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0500","first-page":"86","article-title":"Proton pump inhibitors do not increase the risk of acute rejection","volume":"72","author":"van Boekel","year":"2014","journal-title":"Neth J Med"},{"key":"10.1016\/j.trre.2018.11.001_bb0505","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1177\/0091270011412968","article-title":"Omeprazole impairs the absorption of mycophenolate mofetil but not of enteric-coated mycophenolate sodium in healthy volunteers","volume":"52","author":"Kees","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.trre.2018.11.001_bb0510","article-title":"A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient","author":"Maguire","year":"2011","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0515","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/MOG.0b013e32834bb818","article-title":"Treatment of Helicobacter pylori","volume":"6","author":"Selgrad","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.trre.2018.11.001_bb0520","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0091270004271555","article-title":"The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil","volume":"45","author":"Naderer","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.trre.2018.11.001_bb0525","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1021\/mp200563a","article-title":"P-glycoprotein-based loperamide-cyclosporine drug interaction at the rat blood-brain barrier: prediction from in#spcent;vitro studies and extrapolation to humans","volume":"9","author":"Hsiao","year":"2012","journal-title":"Mol Pharm"},{"key":"10.1016\/j.trre.2018.11.001_bb0530","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2165\/00003088-200140040-00004","article-title":"Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients","volume":"40","author":"Wallemacq","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2018.11.001_bb0535","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","article-title":"Clinical pharmacokinetics of tacrolimus","volume":"29","author":"Venkataramanan","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2018.11.001_bb0540","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/00912700122009999","article-title":"Effect of low- and high-fat meals on tacrolimus absorption following 5#spcent;mg single oral doses to healthy human subjects","volume":"41","author":"Bekersky","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.trre.2018.11.001_bb0545","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation","volume":"53","author":"Hesselink","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2018.11.001_bb0550","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/TP.0b013e31826bc400","article-title":"Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation","volume":"94","author":"Niioka","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0555","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/TP.0b013e3182177502","article-title":"Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity","volume":"91","author":"Metalidis","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0560","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.2165\/00003495-200767130-00012","article-title":"Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients","volume":"67","author":"Cross","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.trre.2018.11.001_bb0565","author":"Agency EM"},{"key":"10.1016\/j.trre.2018.11.001_bb0570","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/TP.0b013e3182962cc1","article-title":"Conversion from twice-daily tacrolimus capsules to once-daily#spcent;extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients","volume":"96","author":"Gaber","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0575","author":"Agency EM"},{"key":"10.1016\/j.trre.2018.11.001_bb0580","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/00003088-200140080-00002","article-title":"Clinical pharmacokinetics of sirolimus","volume":"40","author":"Mahalati","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2018.11.001_bb0585","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/FTD.0b013e31816babef","article-title":"Role of pharmacogenetics of immunosuppressive drugs in organ transplantation","volume":"30","author":"Thervet","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.trre.2018.11.001_bb0590","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1177\/009127009903901107","article-title":"The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin)","volume":"39","author":"Zimmerman","year":"1999","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.trre.2018.11.001_bb0595","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1600-6143.2005.00745.x","article-title":"Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy","volume":"5","author":"Anglicheau","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2018.11.001_bb0600","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2018.11.001_bb0605","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1592\/phco.22.3.154.33542","article-title":"Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants","volume":"22","author":"Kovarik","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.trre.2018.11.001_bb0610","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2013.78","article-title":"Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation","volume":"3","author":"Moes","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.trre.2018.11.001_bb0615","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/00007890-199404270-00007","article-title":"Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a#spcent;concentration-controlled comparison with the commercial formulation","volume":"57","author":"Mueller","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2018.11.001_bb0620","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2165\/00003495-200161130-00006","article-title":"Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation","volume":"61","author":"Dunn","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.trre.2018.11.001_bb0625","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40262-012-0007-8","article-title":"Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation","volume":"51","author":"Bergmann","year":"2012","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.trre.2018.11.001_bb0630","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/gut.39.1.63","article-title":"Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration","volume":"39","author":"Van Os","year":"1996","journal-title":"Gut"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X18301010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X18301010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T16:04:43Z","timestamp":1760630683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X18301010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":126,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S0955470X18301010"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2018.11.001","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppressive drugs and the gastrointestinal tract in renal transplant patients","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2018.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}